Drugs / IBI346 CAR-T
last change May 2023 re-read 3 minutes ago

IBI346 CAR-T

Cell therapy

Developed for
refractory plasma cell neoplasm
Investigated by
Innovent Biologics (Suzhou) Co. Ltd. · The First Affiliated Hospital of Soochow University

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05270928 Apr → Dec 2022 refractory plasma cell neoplasm The First Affiliated Hospital of Soochow University Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IBI346 CAR-T “IBI346 Antibody and IBI346 CAR-T cell injection” NCT05270928 ↗
Modality Cell therapy “IBI346 Antibody and IBI346 CAR-T cell injection” NCT05270928 ↗